Evidence map›Paper›PMID 41668812›Full record

ReviewFrontiers in pharmacology2025

Epidemiology and diagnostic of MASLD in Latin America: a yet to be met challenge.

Carolina Elizabeth Olaez-Ramos, Karla Lizette Mojica-Zamudio, Ana Sandoval-Rodríguez, Juan Armendáriz-Borunda

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. A global commitment to addressing chronic liver disease.The Lancet regional health. Europe · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Carolina Elizabeth Olaez-Ramos *Department of Molecular Biology and Genomics, Institute for Molecular Biology in Medicine and Gene Therapy, Health Sciences University Center, Universidad de Guadalajara, Guadalajara, Mexico.
Karla Lizette Mojica-Zamudio *Department of Molecular Biology and Genomics, Institute for Molecular Biology in Medicine and Gene Therapy, Health Sciences University Center, Universidad de Guadalajara, Guadalajara, Mexico.
Ana Sandoval-RodríguezDepartment of Molecular Biology and Genomics, Institute for Molecular Biology in Medicine and Gene Therapy, Health Sciences University Center, Universidad de Guadalajara, Guadalajara, Mexico.
Juan Armendáriz-BorundaDepartment of Molecular Biology and Genomics, Institute for Molecular Biology in Medicine and Gene Therapy, Health Sciences University Center, Universidad de Guadalajara, Guadalajara, Mexico.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as a major global health concern, affecting more than one-third of the adult population worldwide. Notably, Latin America exhibits the highest regional prevalence, with recent estimates of 44.4%. This elevated burden is attributed to the convergence of risk factors that render the population particularly vulnerable. These include high rates of obesity and type 2 diabetes

Indexed as

diagnosticsepidemiologyLATAMMASLDMexico

Identifiers

PMID41668812
PMCPMC12883381

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.